Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.

Erin L Schenk

TitleAsst Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus

    Collapse Biography 
    Collapse education and training
    Mayo Medical School, Rochester, MNM.D.05/2011
    Mayo Graduate Schoole, Rochester, MNPh.D.05/2011Immunology
    Mayo Clinic Internal Medicine Residence, Rochester, MN6/2014
    Mayo Clinic Hematology/Medical Oncology Fellowship, Rochester, MN3/2018
    Collapse awards and honors
    2017 - 2018IASLC Academy Award, IASLC
    2018Finalist, Immuno-Oncology Young Investigators Forum
    2018Outstanding Fellow Award, Highest Rated and Top Abstract, Minnesota Society of Clinical Oncology

    Collapse Overview 

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Johnson AM, Bullock BL, Neuwelt AJ, Poczobutt JM, Kaspar RE, Li HY, Kwak JW, Hopp K, Weiser-Evans MCM, Heasley LE, Schenk EL, Clambey ET, Nemenoff RA. Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma. J Immunol. 2020 Mar 16. PMID: 32179637.
      View in: PubMed
    2. Failing JJ, Ho TP, Yadav S, Majithia N, Riaz IB, Shin JY, Schenk EL, Xie H. Safety of Influenza Vaccine in Patients With Cancer Receiving Pembrolizumab. JCO Oncol Pract. 2020 Feb 06; JOP1900495. PMID: 32048920.
      View in: PubMed
    3. Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2019 Nov 21. PMID: 31859066.
      View in: PubMed
    4. Schenk EL, Mandrekar SJ, Dy GK, Aubry MC, Tan AD, Dakhil SR, Sachs BA, Nieva JJ, Bertino E, Lee Hann C, Schild SE, Wadsworth TW, Adjei AA, Molina JR. A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study. J Thorac Oncol. 2020 Jan; 15(1):110-119. PMID: 31605793.
      View in: PubMed
    5. Bullock BL, Kimball AK, Poczobutt JM, Neuwelt AJ, Li HY, Johnson AM, Kwak JW, Kleczko EK, Kaspar RE, Wagner EK, Hopp K, Schenk EL, Weiser-Evans MC, Clambey ET, Nemenoff RA. Tumor-intrinsic response to IFN? shapes the tumor microenvironment and anti-PD-1 response in NSCLC. Life Sci Alliance. 2019 06; 2(3). PMID: 31133614.
      View in: PubMed
    6. Kleczko EK, Kwak JW, Schenk EL, Nemenoff RA. Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer. Front Immunol. 2019; 10:954. PMID: 31134065.
      View in: PubMed
    7. Pacheco JM, Camidge DR, Doebele RC, Schenk E. A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer. Front Oncol. 2019; 9:195. PMID: 30984621.
      View in: PubMed
    8. Bunn PA, Schenk E, Pacheco J, Dimou A. New Developments in Neoadjuvant Therapy for Lung Cancer. Oncology (Williston Park). 2019 Mar 13; 33(3):101-6, 109. PMID: 30866032.
      View in: PubMed
    9. Pacheco J, Schenk E. CDK4/6 inhibition alone and in combination for non-small cell lung cancer. Oncotarget. 2019 Jan 18; 10(6):618-619. PMID: 30774754.
      View in: PubMed
    10. Schenk E, Boland J, Mansfield A, Aubry MC, Dietz A. Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma. Med Oncol. 2017 Aug; 34(8):140. PMID: 28711968.
      View in: PubMed
    11. Schenk E, Hendrickson AE, Northfelt D, Toft DO, Ames MM, Menefee M, Satele D, Qin R, Erlichman C. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies. Invest New Drugs. 2013 Oct; 31(5):1251-6. PMID: 23543109.
      View in: PubMed
    12. Schenk EL, Koh BD, Flatten KS, Peterson KL, Parry D, Hess AD, Smith BD, Karp JE, Karnitz LM, Kaufmann SH. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. Clin Cancer Res. 2012 Oct 01; 18(19):5364-73. PMID: 22869869.
      View in: PubMed
    13. Cabrera R, Schenk EL, Nava-Parada P, Bell MP, Van Keulen VP, Marler RJ, Felts SJ, Pease LR. Retraction: Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J Immunol. 2010 Jun 01; 184(11):6556. PMID: 20483796.
      View in: PubMed
    14. Radhakrishnan S, Cabrera R, Schenk EL, Nava-Parada P, Bell MP, Van Keulen VP, Marler RJ, Felts SJ, Pease LR. Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J Immunol. 2008 Sep 01; 181(5):3137-47. PMID: 18713984.
      View in: PubMed
    15. Heckman KL, Schenk EL, Radhakrishnan S, Pavelko KD, Hansen MJ, Pease LR. Fast-tracked CTL: rapid induction of potent anti-tumor killer T cells in situ. Eur J Immunol. 2007 Jul; 37(7):1827-35. PMID: 17549735.
      View in: PubMed
    16. Hildebrand WH, Turnquist HR, Prilliman KR, Hickman HD, Schenk EL, McIlhaney MM, Solheim JC. HLA class I polymorphism has a dual impact on ligand binding and chaperone interaction. Hum Immunol. 2002 Apr; 63(4):248-55. PMID: 12039406.
      View in: PubMed
    17. Turnquist HR, Schenk EL, McIlhaney MM, Hickman HD, Hildebrand WH, Solheim JC. Disparate binding of chaperone proteins by HLA-A subtypes. Immunogenetics. 2002 Feb; 53(10-11):830-4. PMID: 11862383.
      View in: PubMed
    18. Turnquist HR, Vargas SE, Schenk EL, McIlhaney MM, Reber AJ, Solheim JC. The interface between tapasin and MHC class I: identification of amino acid residues in both proteins that influence their interaction. Immunol Res. 2002; 25(3):261-9. PMID: 12018464.
      View in: PubMed
    Schenk's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description

    Copyright © 2020 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)